Frank L. Meyskens
Medicine, School of Medicine
UCI Chao Family Comprehensive Cancer Center, Biological Chemistry, School of Medicine
Phone: (714) 456-6310
Email: flmeyske@uci.edu
http://www.ucihs.uci.edu/biochem/faculty/meyskens.html
http://www.faculty.uci.edu/profile.cfm?faculty_id=3087
Frank Meyskens
Dr. Meyskens’ current research interests are in two areas:
- Three major activities in chemoprevention:
- Development of new chemoprevention agents. They are developing and implementing a series of new trials including lovastatin and melanoma, SAMe and liver cancer, Erlotinib and pancreas cancer, Erlotinib and ACF - colon cancer, and curcumin and ACF – colon cancer. Each protocol has an extensive translational component and in aggregate involve several other institutions (UCSD, U. Utah, U. Arizona, Dana Farber, Harvard, U. Miami, U South Florida).
- Conduct phase III randomized trial of Bowman-Burke Inhibitor and oral leukoplakka. Approximately two more years will be required to complete this trial.
- Completion and extension of randomized placebo controlled phase III trial of difluoromethylornithine plus sulindac for the prevention of colorectal polyps, the major precursor in humans for colorectal cancer. The results have just been obtained and a spectacular effect was demonstrated. Advanced adenomas were reduced by 90% as were multiple adenomas.
- Redox regulation in cutaneous human melanoma. For the past twelve years Dr. Meyskens has been detailing these events at the basic level and a broad-based team of basic and clinical investigators have been brought together to pursue this goal. His particular interest has been in understanding the transcriptional response to redox stress with an emphasis on redox effector factor–7/apurinic–apyrenidinic enducolea (Ref-1/APE-1) and the development of inhibitosr of this key protein for prevention and treatment indications. In the last few years they have explored extensively the possible role of heavy redox-active metals in the etiology and pathogenesis of cutaneous melanoma.
Selected Publications:
Gidanian, S., Mentelle, M., Meyskens, F. L., Jr., and Farmer, P. J. (2008). Melanosomal Damage in Normal Human Melanocytes Induced by UVB and Metal Uptake-A Basis for the Pro-oxidant State of Melanoma. Photochem Photobiol 84(3), 556-564.
Meyskens, F. L., Jr. (2008). Another negative chemoprevention trial: what can we learn? Clin Cancer Res 14(1), 2-3.
Meyskens, F. L., Jr., and Berwick, M. (2008). UV or not UV: metals are the answer. Cancer Epidemiol Biomarkers Prev 17(2), 268-70.
Ngo-Metzger, Q., August, K. J., Srinivasan, M., Liao, S., and Meyskens, F. L., Jr. (2008). End-of-Life care: guidelines for patient-centered communication. Am Fam Physician 77(2), 167-74.
Simoneau, A. R., Gerner, E. W., Nagle, R., Ziogas, A., Fujikawa-Brooks, S., Yerushalmi, H., Ahlering, T. E., Lieberman, R., McLaren, C. E., Anton-Culver, H., and Meyskens, F. L., Jr. (2008). The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17(2), 292-9.
Zell, J. A., Cinar, P., Mobasher, M., Ziogas, A., Meyskens, F. L., Jr., and Anton-Culver, H. (2008). Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol 26(1), 66-75. |
